Reprint
Cancer Immunology
Edited by
December 2021
328 pages
- ISBN978-3-0365-2573-0 (Hardback)
- ISBN978-3-0365-2572-3 (PDF)
This book is a reprint of the Special Issue Cancer Immunology that was published in
Biology & Life Sciences
Medicine & Pharmacology
Summary
The past decade has seen immunotherapy rise to the forefront of cancer treatment. This Special Issue of Cancers aims to elaborate on the latest developments, cutting-edge technologies, and prospects in cancer immunology and immunotherapy. Seventeen exceptional studies, including original contributions and review articles, written by international scientists and physicians, primarily concerning the fields of tumor biology, cancer immunology, therapeutics, and drug development, comprise the main body of this Special Issue.
Format
- Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
NKG2D; CAR T; IL-7; prostate cancer; cell therapy; CD19-CAR-T; B cell aplasia; KIR; PD-1; inhibitory CAR; tumor-infiltrating lymphocytes; tumor microenvironment; immunotherapy; NK cells; cancer stem cells (CSCs); antibody-dependent cellular cytotoxicity (ADCC); differentiation; cytotoxicity; IFN-γ; osteoclasts; MICA/B mAb; DNA methylation; RNA methylation; S-adenosylmethionine (SAM); cancer; tumor microenvironment; innate immunity; adaptive immunity; T cells; m6A; PD-L1; resistance; immune checkpoints; immunotherapy; cancer vaccine; combination immunotherapy; TCR diversity; organ transplantation; carcinoma; epidemiologic studies; immunosuppression; CTLA-4; Treg cells; immune checkpoint inhibitors; CD28; antigen-presenting cells; PD-L1; IL15; colon cancer; melanoma; tumor microenvironment; uveal; immunotherapy; BAP1; tumor microenvironment; anti-PD-1; anti-CTLA-4; TIL; classical and endemic Kaposi Sarcoma; systemic treatment; multi-state modelling; treatment free interval; chemotherapy; interferon; triple negative breast cancer; tumor microenvironment; immunomodulation; bispecific antibody; sortase A; chemo-enzymatic approach; anti-CD20 antibody; Fab; BiFab; colorectal cancer; immune checkpoints; dendritic cells; Atypical Chemokine Receptor 4 (ACKR4); T-cell priming; immune checkpoint blockade; primary liver cancer; kynurenine pathway; immune evasion; indoleamine 2,3 dioxygenase 1; tryptophan 2,3 dioxygenase 2; IDO inhibitor; colorectal cancer; tumor microenvironment; antigen presenting cells; T cells; n/a